logo
Plus   Neg
Share
Email

HeidelbergCement Q4 RCO Up, But Revenue, Sale Volume Down; Sees Positive Demand

HeidelbergCement (HDELY.PK) reported Tuesday that its fourth-quarter result from current operations or RCO grew 3 percent to 603 million euros from last year's 584 million euros.

RCO margin was 13.2 percent, up from 12.4 percent a year ago.

Result from current operations before depreciation and amortisation or RCOBD grew 13 percent to 968 million euros from prior year's 858 million euros. RCOBD margin grew to 21.2 percent from 18.3 percent a year ago.

Revenue for the quarter, meanwhile, declined 3 percent to 4.58 billion euros from last year's 4.70 billion euros. On a like-for-like basis, revenue dropped 5 percent.

Cement sales volumes declined 4 percent to 31.4 million tonnes, and aggregates volume dropped 2 percent to 75.0 million tonnes.

Looking ahead, HeidelbergCement expects demand to further develop positively in many markets in the 2020 business year, in particular in the emerging markets.

The company will release the consolidated financial statements including the outlook for the business year 2020 on March 19.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) expects that its first-quarter operating profit will increase about 2.73 percent from last year, sales will also increase 4.98 percent. JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered.
Follow RTT
>